AnaptysBio reports Phase 2b RA trial success; rosnilimab hits primary endpoint, 69% CDAI LDA at week 14

ANAPTYSBIO, INC

Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).
At week 14, 69% of rosnilimab-treated patients achieved CDAI low disease activity, described as highest ever reported.
Favorable safety: no malignancies, no MACE, no serious infection elevation vs placebo; discontinuations low at 1-2%.
Full week 28 data expected Q2 2025; top-line week 12 rosnilimab UC data now anticipated in Q4 2025.
CEO states results exceed target product profile in ~$20B U.S. RA market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.